Pharmacological Management of Schizophrenia
A number of different pharmacological agents have been shown to be effective in the management of schizophrenia. These pharmacological agents have been variously named antischizophrenic, antipsychotic, neuroleptic, and major tranquilizers. Though these medications do significantly ameliorate the symptoms of schizophrenia, they are not specifically anti-schizophrenic because they are effective against a number of psychotic illnesses. The term neuroleptic is a Greek derivative that literally means to take hold of the nerves. It was first used by Delay and Deniker in 1955 in reference to both chlorpromazine and reserpine (Deniker, 1983) because their extrapyramidal effects resembled central nervous system diseases. By common usage, neuroleptics came to be used interchangeably with the term antipsychotic medications. Novel antipsychotic agents exist that do not have prominent extrapyramidal side effects (e. g., clozapine). These have been called atypical neuroleptics, though a consensus is lacking on a clear definition of the term atypical.
KeywordsNegative Symptom Dopamine Agonist Tardive Dyskinesia Neuroleptic Malignant Syndrome Antipsychotic Agent
Unable to display preview. Download preview PDF.
- Bannon, M. J., & Roth, R. H. (1983). Pharmacology of mesocortical dopamine neurons. Pharmacological Review, 35, 53–68.Google Scholar
- Bunney B. S., & Aghajanian, G. (1974). In E. Usdin & S. H. Snyder (Eds.), Frontiers in catecholamine research. Oxford: Pergammon Press.Google Scholar
- Casey, D. E. (1983). Tardive dyskinesia: What is the natural history? International Drug Therapy Newsletter, 18, 13–16.Google Scholar
- Deniker, P. (1983). Discovery of the clinical uses of neuroleptics. In M. J. Parnham & J. Bruinvels (Eds.), Discoveries in Pharmacology, Volume 1: Psycho-and Neurophar-macology (pp. 163–180). New York: Elsevier Science.Google Scholar
- Fuster, J. (1980). The prefrontal cortex. New York: Raven Press.Google Scholar
- Hogan, T. P., Awad, A. G., & Eastwood, M. R. (1985). Early subjective response and prediction of outcome to neuroleptic therapy in schizophrenia. Canadian Journal of Psychiatry, 30, 246–248.Google Scholar
- Hogarty, G. E., Schooler, N. R., Ulrich, R., Mussare, F., Ferro, P., & Herron, E. (1979). Fluphenazine and social therapy in the aftercare of schizophrenic patients. Relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydro-chloride. Archives of General Psychiatry 36, 1283–1294.PubMedCrossRefGoogle Scholar
- Iversen, S. E., & Iversen, L. L. (1981). Behavioral pharmacology (2nd ed.). New York: Oxford University Press.Google Scholar
- Jeste, D. V., & Wyatt, R. J. (1982). Understanding and treating tardive dyskinesia (p. 84). New York: Guilford Press.Google Scholar
- Weinberger, D. R., & Kleinman, J. E. (1986) Observations on the brain in schizophrenia. In R. E. Hales & J. A. Frances (Eds.), Psychiatry update: American Psychiatric Association annual review (Vol. 5, pp. 42–67). Washington DC: American Psychiatric Association Press.Google Scholar
- Wong, D. F., Wagner, H. N., Tune, L. E., Dannais, R. F., Pearlson, G. D., Links, J. M., Tamminga, C. A., Broussolle, E. P., Ravert, M. T., Wilson, A. A., Thomas Toung, J. K., Malat, J., Williams, J. A., O’Tuane, L. A., Snyder, S. M., Kuhar, M. J., Gjedde, A. (1986). Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. Science, 234, 1558–1563.PubMedCrossRefGoogle Scholar